Cardiac disease company AnaBios said on Thursday that it has entered into a partnership with Sanofi to develop a new treatment for atrial fibrillation, including the CardioPRIME technology, with focus on compounds designed to modulate a novel cardiac ion channel target.
CardioPRIME is part of AnaBios' broad portfolio of ex-vivo human safety and efficacy evaluation technology, which employs primary human cells and tissues--maintained in a fully-functional state outside of the body--for preclinical laboratory study of drug activity.
Under the terms of this agreement, AnaBios will acquire development and commercialisation rights to an entire family of promising compounds addressing the global atrial fibrillation market, which is estimated to reach USD16.17bn by 2020 according to a recent report by Grand View Research.
The company's CardioPRIME technology demonstrated the ability to predict human clinical outcomes with greater than 95% accuracy (Nguyen et al, Frontiers in Physiology 2017) in a recent published peer-reviewed article.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal